Pharmaceuticals, Biotechnology and Life Sciences
Novartis has reported new data suggesting, for the first time, that Cosentyx (secukinumab) may modify the course of moderate-to-severe psoriasis leading to long-term, treatment-free skin clearance.
Novartis has reported new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx (secukinumab) rapidly regain clear or almost clear skin (Psoriasis Area Severity Index, PASI 90 to 100) following relapse during a treatment pause. Also showed no anti-secukinumab antibodies were observed during retreatment.
Ablynx and Merck KGaA (Germany) have reported encouraging results from a study in psoriasis patients with the bi-specific Nanobody anti-IL-17A/F (M1095), via a clinical trials website (https://clinicaltrials.gov/NCT02156466).